A
Alcista
Alcista · 25%MLAB
$100.37
Precio del escenario
$127.740
+1.597 (+1.25%)Al cierre
Loading chart…
- Máximo
- 129.060
- Apertura
- 125.180
- Precio medio ponderado por volumen
- 127.27
- Volumen
- 100.25K
- Capitalización
- 458.17M
- Mínimo
- 125.000
- Importe
- 12.76M
- EV/EBITDA, TTM
- 14.22
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring.
Análisis de IA of Mesa Laboratories Inc (MLAB)
MantenerMesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.
Recomendaciones de analistas (2)
-22.50% Potencial de caída
Comprar
1 Comprar
1 Mantener
0 Vender
Actual: 127.74
Mínimo
83.00
Promedio
99.00
Máximo
115.00
Wells Fargo
Equal Weight
$94
2026-02-04
Wells Fargo
2026-02-04
Precio objetivo
$94
Equal Weight
Wells Fargo
Equal Weight
$83
2025-12-15
Wells Fargo
2025-12-15
Precio objetivo
$83
Equal Weight
Jefferies
Comprar
$115
2025-11-07
Jefferies
2025-11-07
Precio objetivo
$115
Comprar
Wells Fargo
Equal Weight
$67
2025-08-07
Wells Fargo
2025-08-07
Precio objetivo
$67
Equal Weight
Wells Fargo
Infraponderar
$100
2025-05-30
Wells Fargo
2025-05-30
Precio objetivo
$100
Infraponderar
Métricas de valoración
El PER previsto actual de Mesa Laboratories Inc (MLAB) es 34.48, frente a su media de 5 años de 30.05.
Escenarios de precio de Alphio AI para MLAB
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con MLAB en cartera
Cronología de eventos
Noticias
9.508-17NASDAQ.COMMesa Laboratories Reports Q1 2027 Earnings with Mixed Results
9.508-03NewsfilterMesa Laboratories to Release Q1 2027 Financial Results on August 10, 2026
8.007-06seekingalphaMesa Laboratories Declares Quarterly Dividend of $0.16
- 8.007-06Newsfilter
Mesa Laboratories Declares Quarterly Dividend
9.505-27FoolMesa Laboratories Shares Plunge 19.5% Following Q4 Earnings Report
Preguntas frecuentes sobre MLAB, respondidas por Alphio AI
Mesa Laboratories, Inc. designs and manufactures life sciences tools and critical control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. The Company's segments include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Sterilization and Disinfection Control segment manufactures and sells biological, chemical and cleaning indicators. Clinical Genomics segment develops, manufactures and sells genetic analysis tools and related consumables and services. Biopharmaceutical Development segment develops, manufactures, sells and services automated systems for protein analysis and peptide synthesis solutions. Calibration Solutions segment develops, manufactures, sells and services control products using principles of advanced metrology to enable customers to measure and calibrate critical parameters in applications, such as renal care, environmental and process monitoring. It operates in the Healthcare sector (INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, A industry).
Mesa Laboratories Inc is currently a hold. The stock closed at $127.51, showing a year-to-date change of +60.53%, which indicates strong performance over the year. However, the RSI is at 40.74, suggesting it is nearing oversold territory, which could indicate a potential rebound. The forward P/E ratio of 34.48 is high, reflecting strong growth expectations, but the recent earnings report showed a revenue miss, which is a concern. The main risk is the company’s recent volatility, with a 19.5% drop following the Q4 earnings report, indicating uncertainty in future performance.
2 analysts cover MLAB: 1 rate it Buy, 1 Hold and 0 Sell. The average price target is 99.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.